Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200 Day Moving Average – Here’s Why

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.78 and traded as high as $5.76. Cumberland Pharmaceuticals shares last traded at $5.61, with a volume of 38,343 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Cumberland Pharmaceuticals has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The company has a market capitalization of $84.04 million, a P/E ratio of -11.45 and a beta of 0.09. The business has a 50-day moving average of $4.21 and a 200-day moving average of $3.78. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.95 and a quick ratio of 0.79.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). The company had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.

Institutional Trading of Cumberland Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC bought a new stake in Cumberland Pharmaceuticals in the fourth quarter worth $1,358,000. Dimensional Fund Advisors LP lifted its stake in Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after purchasing an additional 27,980 shares during the last quarter. Bridgeway Capital Management LLC lifted its stake in Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after purchasing an additional 4,200 shares during the last quarter. Marshall Wace LLP bought a new stake in Cumberland Pharmaceuticals in the fourth quarter worth about $192,000. Finally, Geode Capital Management LLC lifted its stake in Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after purchasing an additional 5,653 shares during the last quarter. 15.51% of the stock is currently owned by institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.